FDA Warns of Fatal Liver Injuries Tied to Drug It Wants Pulled From Market Eight deaths and dozens of DILI cases linked to avacopan for ANCA-associated vasculitis

When a company doesn't cooperate with FDA's request, the law gives companies the opportunity to delay the inevitable.
#FDA #Congress #Tavneos
www.medpagetoday.com/rheumatology...

FDA points to liver injury with Amgen's Tavneos The FDA raises the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.

The #FDA has ramped up the pressure on #Amgen to #withdraw #Tavneos for a rare #vasculitis condition from the market, with a report saying it has identified cases of serious #liverinjury – including deaths – among people taking the drug.

The US FDA has linked the Amgen-manufactured drug Tavneos to serious liver injuries. Eight deaths have been reported in connection with the medication, according to the agency's statement on Tuesday. #US #Tavneos #Amgen

EMA looks into 'data integrity' issue with Amgen's Tavneos Concerns about efficacy data in the main trial behind the approvals of Amgen and CSL Vifor's Tavneos have triggered an EU review.

The #EMA's human medicines committee has started a review of oral complement C5 inhibitor #Tavneos, prompted by information that the regulator says raises questions about the integrity of the #data from the pivotal ADVOCATE study.

Amgen Breathes Success in Second Quarter 2025 Financial Results Amidst New Product Growth Amgen's second quarter 2025 financial results indicate a robust earnings growth attributed to innovative products and strong sales performance, signaling positive future prospects.

Amgen Breathes Success in Second Quarter 2025 Financial Results Amidst New Product Growth #USA #Amgen #Thousand_Oaks #Repatha #TAVNEOS

Tavneos (avacopano) | Relatório de avaliação de financiamento público disponível na Infomed Infarmed

Tavneos (avacopano) | Relatório de avaliação de financiamento público disponível na Infomed
➡ swki.me/fMZyciq5
#infarmed #tavneos #medicamentos #financiamentopúblico